Published 2018-07-26
Zuhirman Zamzami


Objective: To evaluate the success rates of tamsulosin and dutasteride as medical therapy based on international prostate symptom score (IPSS) in symptomatic benign prostatic hyperplasia (BPH) patients. Materials & Methods: We reviewed medical records of the symptomatic BPH patients in Arifin Achmad Regional General Hospital, Pekanbaru, Riau Province, Indonesia in 2011-2016. The previous and after IPSS of administering tamsulosin 0.2 mg or 0.4 mg or dutasteride 0.5 mg as a single therapy and tamsulosin 0.4 mg with dutasteride 0.5 mg as a combination therapy were assessed. Wilcoxon test was used for statistical analysis. Approval on the study was obtained from the Ethical Review Board for Medicine and Health Research, Medical Faculty, University of Riau. Results: 100 patients fulfilled the inclusion criteria. The results showed 50% patients with mild IPSS and 50% patients with severe IPSS before the medication. 70% patients administered tamsulosin 0.2 mg as first-line therapy, 35% patients administered medication for 6 months-1 year, and 3% patients with mild IPSS, 44% with moderate IPSS and 53% with severe IPSS after the medication. The Wilcoxon test showed there was a significant different (p<0.005) between IPSS levels before and after the medication with success rate 18%. Conclusion: There were good success rate of tamsulosin 0.2 mg, tamsulosin 0.4 mg, dutasteride 0.5 mg as single therapy and tamsulosin 0.4 mg with dutasteride 0.5 mg as combination therapy in symptomatic BPH patients based on IPSS, and the medical therapy are still recommended.



Benign prostatic hyperplasia, international prostate symptom score, medical therapy


National Institute of Diabetes and Digestive and Kidney Diseases. Prostate enlargement: Benign prostatic hyperplasia. Emedicine website. NIH publication No.14-3012 August 2014. Accessed 9 September 2015.

Soetapa H, Djatisoesanto W, Soebadi DM. Prostate volume measurement using digital rectal examination and transrectal ultrasound by the same operator compared to the one using transabdominal ultrasound by different operator. Indonesian Journal of Urology. 2006; 14: 34-9.

Aprilia RD. Correlation between leukosituria incidence and prostate volume in BPH patients by abdominal ultrasound. Website. Accessed 29 September 2015.

Roehrborn CG. Benign Prostatic Hyperplasia: Etiology, phatophysiology, epidemiology, and natural history. In: Campbell’s Urology, 10th Edition. Editor: Walsh PC, Retik AB, Vaughan ED, dan Wein AJ. Philadelphia: WB Saunders Co.; 2012. p. 2570-91.

Indonesian Urological Association. Guidelines on benign prostate hyperplasia; 2015.

McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011; 185: 1793-803.

Gerber GS, Brendler CB. Evaluation of the Urologic Patient: History, Physical Examination, and Urinalysis. In: Campbell-Walsh Urology. 10th edition. Philadelphia: Elsevier Saunders; 2012. p. 71-80.

Indonesian Urological Association. Temporary consensus guidelines on benign prostate hyperplasia in Indonesia; 2000. p. 5-14.

Dwindra M. Profile of Benign Prostate Hyperplasia in Arifin Achmad Pekanbaru 2005-2006 [Scription]. Pekanbaru: Medical Faculty, University Riau; 2007.

Sabri M. Profile Benign Prostate Hyperplasia underwent in Arifin Achmad Regional General Hospital Pekanbaru 2009-2010 [Scription]. Pekanbaru: Medical Faculty, University Riau; 2011.

Fitriana N, Zuhirman, Suyanto. Correlation between benign prostate hypertrophy and erectile dysfunction in Arifin Achmad General Hospital Pekanbaru, Riau Province. [Sription]. Medical Faculty, Riau University; January 2014.

Chandrasegaran K. Profile of Prostate Symptome Score in Benign Prostate Hyperplasia patients in Adam Malik Hospital Medan. Accessed from: 26 Desember 2016.

Mondang, Monoarfa, Salem. Correlation between IPSS and Quality of Life in BPH with LUTS patients in Kandou Hospital. eCI [serial on the internet]. 2015; 3(1). Accessed from: 26th December 2015.

Shim SR, Kim JH, Chang JH, Shin IS, Hwang SD, Kim KH, et al. Is Tamsulosin 0,2 mg Effective and Safe a First Line Treatment Compared with Other Alpha Blocker?: A Meta-Analysis and a Moderator Focused Study. Yonsei Med J. 2016; 57(2): 407-18. Diakses dari: http://10.3349/ymj.2016.57.2.407. [Pubmed: 26847294]

Naraya P, Indudhara R. Conferences and Review: Pharmacotherapy for Benign Prostatic Hyperplasia. West J Med. 1994; 161: 495-506.

Djavas B, Handl MJ, Dianat S. Combined Medical Treatment Using Dutasteride and Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia. Expert Opin Pharmacother. 2010; 11(15): 2535-47. Dikutip dari: http://10.1517/14656566.2010.516901. [Pubmed: 20854184]

Madersbacher S, Marszalek M, Lackner J, Berger P, Schatzl. The Long-Term Outcome of Medical Therapy for BPH. European Urology; 2007. p. 1522-33. Diakses dari:

Roehrborn GC, Siami P, Barkin J, Damiao R, et al. The Effect of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Symptoms in Men with Benign Prostatic Hyperplasia and Prostatic Enlargement: 2 Year Results From the CombAT Study. J Urol. 2008; 179: 616-21. Diakses dari:

Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University